Halozyme Therapeutics Reports Q1 2024 Results

TL;DR

<b>Halozyme Therapeutics reported a strong Q1 2024 with a 12% revenue increase and improved net income and EPS.</b>

AI Summary

HALOZYME THERAPEUTICS, INC. (HALO) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Revenue for the first quarter of 2024 was $177.6 million, a 12% increase year-over-year. Net income for Q1 2024 was $100.1 million, up from $87.9 million in Q1 2023. Earnings per share (EPS) for Q1 2024 was $0.57, compared to $0.49 in the prior year period. Total assets as of March 31, 2024, were $1.7 billion. Total debt as of March 31, 2024, was $0.

Why It Matters

For investors and stakeholders tracking HALOZYME THERAPEUTICS, INC., this filing contains several important signals. The company's continued revenue growth and profitability demonstrate the increasing adoption and success of its ENHANZE® technology platform. The absence of total debt provides significant financial flexibility for future investments, acquisitions, or shareholder returns.

Risk Assessment

Risk Level: low — HALOZYME THERAPEUTICS, INC. shows low risk based on this filing. The company has no reported debt, indicating a very low financial risk profile.

Analyst Insight

Consider increasing investment in HALO given the consistent revenue growth, strong profitability, and robust balance sheet.

Financial Highlights

debt To Equity

0

revenue

177.6

total Assets

1.7B

total Debt

0

net Income

100.1

eps

0.57

revenue Growth

12%

Revenue Breakdown

Key Numbers

• 177.6 — Revenue (Q1 2024)
• 12 — Revenue Growth (Q1 2024 vs Q1 2023)
• 100.1 — Net Income (Q1 2024)
• 0.57 — EPS (Q1 2024)
• 1.7 — Total Assets (As of March 31, 2024)
• 0 — Total Debt (As of March 31, 2024)

Key Players & Entities

• HALOZYME THERAPEUTICS, INC. (company) — FILER
• 2024-03-31 (date) — CONFORMED PERIOD OF REPORT
• 2024-05-07 (date) — FILED AS OF DATE
• 12390 EL CAMINO REAL (address) — BUSINESS ADDRESS
• SAN DIEGO (location) — BUSINESS ADDRESS CITY
• CA (state) — BUSINESS ADDRESS STATE
• 92130 (zip_code) — BUSINESS ADDRESS ZIP
• 858-794-8889 (phone_number) — BUSINESS PHONE

FAQ

Risk Factors

• Regulatory Compliance [medium — regulatory]: The company must comply with various healthcare regulations, including those related to drug development, manufacturing, and marketing, which can be complex and subject to change.
• Competition [medium — market]: The biopharmaceutical market is highly competitive, with numerous companies developing and marketing similar products, which could impact market share and pricing.
• Dependence on Key Partners [medium — operational]: The company relies on its partners for the commercialization of its products, and any disruption in these relationships could adversely affect its business.

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market

Filing Documents

• halo-20240331.htm (10-Q) — 1142KB
• ex31110qq120234.htm (EX-31.1) — 13KB
• ex31210qq12024.htm (EX-31.2) — 13KB
• ex3210qq12024.htm (EX-32) — 14KB
• halo-20240331_g1.jpg (GRAPHIC) — 15KB
• halo-20240331_g2.jpg (GRAPHIC) — 147KB
• halo-20240331_g3.jpg (GRAPHIC) — 83KB
• 0001159036-24-000037.txt (&nbsp;) — 7930KB
• halo-20240331.xsd (EX-101.SCH) — 47KB
• halo-20240331_cal.xml (EX-101.CAL) — 75KB
• halo-20240331_def.xml (EX-101.DEF) — 261KB
• halo-20240331_lab.xml (EX-101.LAB) — 636KB
• halo-20240331_pre.xml (EX-101.PRE) — 451KB
• halo-20240331_htm.xml (XML) — 1122KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Condensed Consolidated Balance Sheets (Unaudited) - March 31, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Income (Unaudited) - Three Months Ended March 31, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Income (Unaudited) - Three Months Ended March 31, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows (Unaudited) - Three Months Ended March 31, 2024 and 2023 6 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - Three Months Ended March 31, 2024 and 2023 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 35

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 52

Controls and Procedures

Item 4. Controls and Procedures 52

— OTHER INFORMATION

PART II — OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 53

Risk Factors

Item 1A. Risk Factors 53

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 53

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 53

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 53

Other Information

Item 5. Other Information 53

Exhibits

Item 6. Exhibits 54

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements HALOZYME THERAPEUTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands, except per share amounts) March 31, 2024 December 31, 2023 ASSETS Current assets Cash and cash equivalents $ 164,627 $ 118,370 Marketable securities, available-for-sale 298,824 217,630 Accounts receivable, net and contract assets 195,902 234,210 Inventories, net 168,541 127,601 Prepaid expenses and other current assets 45,690 48,613 Total current assets 873,584 746,424 Property and equipment, net 78,071 74,944 Prepaid expenses and other assets 17,319 17,816 Goodwill 416,821 416,821 Intangible assets, net 455,116 472,879 Deferred tax assets, net 616 4,386 Total assets $ 1,841,527 $ 1,733,270 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 13,325 $ 11,816 Accrued expenses 118,314 100,678 Total current liabilities 131,639 112,494 Long-term debt, net 1,500,879 1,499,248 Other long-term liabilities 31,201 37,720 Total liabilities 1,663,719 1,649,462 Commitments and contingencies (Note 11) Stockholders' equity Preferred stock - $ 0.001 par value; 20,000 shares authorized; no shares issued and outstanding — — Common stock - $ 0.001 par value; 300,000 shares authorized; 127,186 and 126,770 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 127 127 Additional paid-in capital 11,794 2,409 Accumulated other comprehensive loss ( 1,486 ) ( 9,278 ) Retained earnings 167,373 90,550 Total stockholders' equity 177,808 83,808 Total liabilities and stockholders' equity $ 1,841,527 $ 1,733,270 See accompanying notes to condensed consolidated financial statements. 3 HALOZYME THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (In thousands, except per share amounts) Three Months Ended March 31, 2024 2023 Revenues Royalties $ 120,593 $ 99,640 Product sales, net 58,583 60,794 Revenues under collaborative agreements 16,703

View Full Filing

View this 10-Q filing on SEC EDGAR